Literature DB >> 15824364

Gadolinium encephalopathy in a patient with renal failure.

Boby Varkey Maramattom1, Edward M Manno, Eelco F M Wijdicks, Edward P Lindell.   

Abstract

Gadolinium chelates are extensively used in MRI studies. Neurotoxicity due to gadolinium chelates is minimal and uncommon. A 57-year-old woman in renal failure developed a subacute encephalopathy after inadvertent repetitive gadolinium contrast administration. An unusual MRI appearance with CSF hyperintensity due to gadolinium diffusion into the CSF is also shown.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15824364     DOI： 10.1212/01.WNL.0000156805.45547.6E

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  19 in total

1.  Gadolinium encephalopathy due to accidental intrathecal administration of gadopentetate dimeglumine.

Authors:  Sönke Arlt; Lukas Cepek; Hans Heino Rustenbeck; Hilmar Prange; Carl Detlev Reimers
Journal:  J Neurol       Date:  2007-04-02       Impact factor: 4.849

2.  Exceeding the limits of the normal blood-brain barrier: quo vadis gadolinium?

Authors:  L M Levy
Journal:  AJNR Am J Neuroradiol       Date:  2007-09-26       Impact factor: 3.825

3.  Intrathecal gadolinium: its time has come?

Authors:  W P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2008-01       Impact factor: 3.825

4.  Persistence of gadolinium contrast enhancement in CSF: a possible harbinger of gadolinium neurotoxicity?

Authors:  F K Hui; M Mullins
Journal:  AJNR Am J Neuroradiol       Date:  2008-07-17       Impact factor: 3.825

5.  Absence of clinical cerebellar syndrome after serial injections of more than 20 doses of gadoterate, a macrocyclic GBCA: a monocenter retrospective study.

Authors:  Gaetano Perrotta; Thierry Metens; Julie Absil; Marc Lemort; Mario Manto
Journal:  J Neurol       Date:  2017-09-27       Impact factor: 4.849

6.  Signal intensity increases in dentate nucleus/globus pallidus/pulvinar on unenhanced T1WI MR images after multiple examinations with gadodiamide.

Authors:  Takao Koiso; Masaaki Yamamoto; Shinya Watanabe; Bierta E Barfod
Journal:  Neuroradiol J       Date:  2019-03-29

Review 7.  Gadolinium retention in the body: what we know and what we can do.

Authors:  Enrico Tedeschi; Ferdinando Caranci; Flavio Giordano; Valentina Angelini; Sirio Cocozza; Arturo Brunetti
Journal:  Radiol Med       Date:  2017-03-30       Impact factor: 3.469

8.  In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents.

Authors:  Enrico Tedeschi; Giuseppe Palma; Antonietta Canna; Sirio Cocozza; Carmela Russo; Pasquale Borrelli; Roberta Lanzillo; Valentina Angelini; Emanuela Postiglione; Vincenzo Brescia Morra; Marco Salvatore; Arturo Brunetti; Mario Quarantelli
Journal:  Eur Radiol       Date:  2016-02-23       Impact factor: 5.315

9.  Neurotoxicity from intrathecal gadolinium administration: Case presentation and brief review.

Authors:  Nick Calvo; Marium Jamil; Scott Feldman; Aashit Shah; Feryal Nauman; Joseph Ferrara
Journal:  Neurol Clin Pract       Date:  2020-02

10.  Neurotoxic manifestations of an overdose intrathecal injection of gadopentetate dimeglumine.

Authors:  Kwan-Woong Park; Soo-Bin Im; Bum-Tae Kim; Sun-Chul Hwang; Jong-Sun Park; Won-Han Shin
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.